GlassScriptPhysician profile
Erika H Brown
NPI 1760445605
$3,579.28
in general payments reported to CMS, 2019-2025
13 companies · $729 in 2025
The $729 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $300 · 2021: $107 · 2022: $394 · 2023: $880 · 2024: $733 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,191.25 | 2019-2025 | Precision7, Total30, Rocklatan |
| Coopervision INC. | $783.94 | 2019-2024 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $456.77 | 2022-2025 | Infuse, Biotrue, Envista Aspire Iol |
| Sun Pharmaceutical Industries INC. | $440.47 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $244.34 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $89.64 | 2019-2023 | |
| Dompe US, INC. | $84.22 | 2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $82.83 | 2019-2020 | |
| Abbvie INC. | $74.24 | 2022-2023 | Lumigan, Vuity, Alphagan P |
| Allergan, INC. | $45.50 | 2019-2020 | |
| Rxsight INC | $45.45 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $22.85 | 2025 | Xdemvy |
| Shire North American Group INC | $17.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.